Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism

NCT05408546 is registered in ClinicalTrials.gov with Translational Sciences, Inc. as lead sponsor.

NCT NCT05408546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Thrombolytic Effects of Ascending Doses of TS23 in Subjects With Intermediate-Risk (Sub-Massive) Acute Pulmonary Embolism
Lead sponsor
Translational Sciences, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 24, 2023
Completion date
November 30, 2026
Enrollment
64 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism